IKT Inhibikase Therapeutics, Inc.
$2.41
Inhibikase Therapeutics, Inc. (IKT) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.3% since its last earnings release on August 11, 2026.
Inhibikase Therapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$2.41
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
Sector
Healthcare
Industry
Biotechnology